Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Publishes New Data on Role of miR-15 in Cardiovascular Disease

Premium

Miragen Therapeutics this week announced the publication of preclinical data showing that a specific microRNA, miR-15, is up-regulated in response to ischemic damage in two model systems.

The data also show that the miRNA contributes to cardiovascular diseases by regulating heart muscle cell death after a heart attack, the company said.

The miRNA is currently the target of a Miragen drug-development program in post-myocardial infarction remodeling. It is covered under Miragen's recent partnership with France's Les Laboratoires Servier (GSN 10/20/2011).

"These findings represent an important step toward optimization of oligonucleotide-based therapies for modulation of cardiac miRNAs," Eric Olson, a researcher at the University of Texas Southwestern Medical Center and Miragen co-founder, said in a statement. “Importantly, this study validates miR-15 as a therapeutic target for the manipulation of cardiac remodeling and function in the setting of ischemic heart disease."

The data appeared in the online edition of Circulation Research.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.